Eikon Therapeutics (NASDAQ:EIKN) Posts Quarterly Earnings Results

Posted by Brenda Bartman on Aug 13th, 2026

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.63) earnings per share (EPS) for the quarter, FiscalAI reports.

Eikon Therapeutics Stock Down 0.9%

Shares of Eikon Therapeutics stock traded down $0.09 on Thursday, hitting $10.33. The stock had a trading volume of 369,448 shares, compared to its average volume of 367,931. The company has a 50 day moving average of $10.02. The stock has a market capitalization of $559.27 million and a price-to-earnings ratio of -4.20. Eikon Therapeutics has a twelve month low of $7.90 and a twelve month high of $17.40.

Institutional Investors Weigh In On Eikon Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG acquired a new position in Eikon Therapeutics in the 2nd quarter valued at approximately $281,000. Bank of New York Mellon Corp bought a new position in shares of Eikon Therapeutics during the second quarter valued at $624,000. Finally, BlackRock Inc. lifted its holdings in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after purchasing an additional 962,046 shares during the period.

Analysts Set New Price Targets

A number of brokerages have weighed in on EIKN. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Finally, Wedbush dropped their price target on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating for the company in a research note on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eikon Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $25.20.

Get Our Latest Report on EIKN

About Eikon Therapeutics

(Get Free Report)

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.